STAT3 and metabolic dysfunction-associated steatotic liver disease: Indeed, we were able to show for the first time that inhibition of STAT3 activity deregulates miRNA expression and in parallel improved steatohepatitis in vitro and in vivo, reducing neutral lipid accumulation and droplets generation, suggesting STAT3 as a potential therapeutic target for NAFLD.